Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › MPLT

Pivotal bioVenture Partners Investment Advisor LLC position in MPLT

MAPLIGHT THERAPEUTICS INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 611,446 shares of MPLT (MAPLIGHT THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.2M, representing 2.54% of its reported portfolio and ranking #11 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed MPLT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)611.45K sh
Reported value held$6.23M
Portfolio Weight2.54%
First reportedQ4 2025
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's MPLT position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in MPLT in Q4 2025 at 611,447 shares (US$10.7M). The position peaked in Q2 2026 at 611,446 shares, worth US$21.9M. Across 4 filings, Pivotal bioVenture Partners Investment Advisor LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 611,446 shares valued at US$6.2M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 611.45K $10.74M New
Q1 2026 611.45K $12.43M Hold
Q2 2026 611.45K $21.91M Hold
Q3 2026 611.45K $6.23M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MPLT and 13F data

MPLT (MAPLIGHT THERAPEUTICS INC) is a Health Care company. 97 other funds we track also report a position in MPLT — the largest reported positions include Novo Holdings A/S (US$132.1M), FCPM III SERVICES B.V. (US$115.6M), 5AM Venture Management, LLC (US$34.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MPLT

All MPLT fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held MPLT?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed MPLT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in MPLT?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 611.45K shares of MPLT (MAPLIGHT THERAPEUTICS INC), valued at $6.23M, representing 2.54% of its reported portfolio and ranking #11.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling MPLT?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in MPLT. The position peaked in Q2 2026 at 611.45K shares.

Which other funds hold MPLT?

Other major institutional holders of MPLT include Novo Holdings A/S, FCPM III SERVICES B.V., 5AM Venture Management, LLC, among 97 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.